Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials

Martín, M.; Loibl, S.; Hyslop, T.; De la Haba-Rodríguez, J.; Aktas, B.; Cirrincione, C.T.; Mehta, K.; Barry, W.T.; Morales, S.; Carey, L.A.; Garcia-Saenz, J.A.; Partridge, A.; Martinez-Jañez, N.; Hahn, O.; Winer, E.; Guerrero-Zotano, A.; Hudis, C.; Casas, M.; Rodriguez-Martin, C.; Furlanetto, J.; Carrasco, E.; Dickler, M.N.

期刊名称European Journal of Cancer
作者Martín, M.; Loibl, S.; Hyslop, T.; De la Haba-Rodríguez, J.; Aktas, B.; Cirrincione, C.T.; Mehta, K.; Barry, W.T.; Morales, S.; Carey, L.A.; Garcia-Saenz, J.A.; Partridge, A.; Martinez-Jañez, N.; Hahn, O.; Winer, E.; Guerrero-Zotano, A.; Hudis, C.; Casas, M.; Rodriguez-Martin, C.; Furlanetto, J.; Carrasco, E.; Dickler, M.N.
卷第117卷
印刷ISSN0959-8049
文件大小908.08KB
发表时间2019-08
DOI10.1016/j.ejca.2019.06.002
页码91-98

发现好书期刊，享受阅读乐趣

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials